Tissue-specific oncogenic activity of KRASA146T

Emily J. Poulin, Asim K. Bera, Jia Lu, Yi Jang Lin, Samantha Dale Strasser, Joao A. Paulo, Tannie Q. Huang, Carolina Morales, Wei Yan, Joshua Cook, Jonathan A. Nowak, Douglas K. Brubaker, Brian A. Joughin, Christian W. Johnson, Rebecca A. Destefanis, Phaedra C. Ghazi, Sudershan Gondi, Thomas E. Wales, Roxana E. Iacob, Lana BogdanovaJessica J. Gierut, Yina Li, John R. Engen, Pedro A. Perez-Mancera, Benjamin S. Braun, Steven P. Gygi, Douglas A. Lauffenburger, Kenneth D. Westover, Kevin M. Haigis

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

KRAS is the most frequently mutated oncogene. The incidence of specific KRAS alleles varies between cancers from different sites, but it is unclear whether allelic selection results from biological selection for specific mutant KRAS proteins. We used a cross-disciplinary approach to compare KRASG12D, a common mutant form, and KRASA146T, a mutant that occurs only in selected cancers. Biochemical and structural studies demonstrated that KRASA146T exhibits a marked extension of switch 1 away from the protein body and nucleotide binding site, which activates KRAS by promoting a high rate of intrinsic and guanine nucleotide exchange factor– induced nucleotide exchange. Using mice genetically engineered to express either allele, we found that KRASG12D and KRASA146T exhibit distinct tissue-specific effects on homeostasis that mirror mutational frequencies in human cancers. These tissue-specific phenotypes result from allele-specific signaling properties, demonstrating that context-dependent variations in signaling downstream of different KRAS mutants drive the KRAS mutational pattern seen in cancer. SIGNIFICANCE: Although epidemiologic and clinical studies have suggested allele-specific behaviors for KRAS, experimental evidence for allele-specific biological properties is limited. We combined structural biology, mass spectrometry, and mouse modeling to demonstrate that the selection for specific KRAS mutants in human cancers from different tissues is due to their distinct signaling properties.

Original languageEnglish (US)
Pages (from-to)738-755
Number of pages18
JournalCancer discovery
Volume9
Issue number6
DOIs
StatePublished - Jun 2019

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Tissue-specific oncogenic activity of KRAS<sup>A146T</sup>'. Together they form a unique fingerprint.

  • Cite this

    Poulin, E. J., Bera, A. K., Lu, J., Lin, Y. J., Strasser, S. D., Paulo, J. A., Huang, T. Q., Morales, C., Yan, W., Cook, J., Nowak, J. A., Brubaker, D. K., Joughin, B. A., Johnson, C. W., Destefanis, R. A., Ghazi, P. C., Gondi, S., Wales, T. E., Iacob, R. E., ... Haigis, K. M. (2019). Tissue-specific oncogenic activity of KRASA146T Cancer discovery, 9(6), 738-755. https://doi.org/10.1158/2159-8290.CD-18-1220